Antibodies with high FcγR affinity and target neoantigens expressed on tumor cell surface induce ADCC, antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), which are significant mechanisms of antibody drugs for cancer therapy. The gene discussed is FCGR2A; the disease is neoplasm.